Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations
Journal of Cystic Fibrosis , Volume 15 - Issue 5 p. 568- 578
The potentiator VX-770 (ivacaftor/KALYDECO™) targets defective gating of CFTR and has been approved for treatment of cystic fibrosis (CF) subjects carrying G551D, S1251N or one of 8 other mutations. Still, the current potentiator treatment does not normalize CFTR-dependent biomarkers, indicating the need for development of more effective potentiator strategies. We have recently pioneered a functional CFTR assay in primary rectal organoids and used this model to characterize interactions between VX-770, genistein and curcumin, the latter 2 being natural food components with established CFTR potentiation capacities. Results indicated that all possible combinations of VX-770, genistein and curcumin synergistically repaired CFTR-dependent forskolin-induced swelling of organoids with CFTR-S1251N or CFTR-G551D, even under suboptimal CFTR activation and compounds concentrations, conditions that may predominate in vivo. Genistein and curcumin also enhanced forskolin-induced swelling of F508del homozygous organoids that were treated with VX-770 and the prototypical CFTR corrector VX-809. These results indicate that VX-770, genistein and curcumin in double or triple combinations can synergize in restoring CFTR-dependent fluid secretion in primary CF cells and support the use of multiple potentiators for treatment of CF.
|, , , , ,|
|Journal of Cystic Fibrosis|
|Organisation||Department of Gastroenterology & Hepatology|
Dekkers, J.F, Van Mourik, P, Vonk, A.M, Kruisselbrink, E, Berkers, G, De Winter-De Groot, K.M, … Beekman, J.M. (2016). Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations. Journal of Cystic Fibrosis, 15(5), 568–578. doi:10.1016/j.jcf.2016.04.007